Semprus Biosciences Corp. closes an $18 million Series B funding round, which CEO David Lucchino says it will use to build out its management team and fund manfuacturing ramp-up for its nanotech catheter coating.
Semprus BioSciences Corp. reeled in $18 million in Series B financing for its nanotech medical device coating.
Semprus CEO David Lucchino told MassDevice that the company will use the proceeds to build a team of "been there, done that" medical device executives and to scale up its manufacturing operations.
"Investor expectations with this round of funding are that we would gain regulatory and clinicial clarity, along with having an initial product in hand to start initial sales. We're looking at the next 24 months as being that window," Lucchino told us.
The Semprus Sustain technology, which was developed at the Mass. Institute of Technology and the University of Washington, is a coating for implanted medical devices designed to prevent blood and bacteria from adhering to the implants. Semprus is initially targeting vascular access products — read catheters — which the company claims kill 56,000 people each year and cost the healthcare system $11.2 billion annually from infections and blood clots.
"Think of it as millions of molecular-sized oak trees that are rooted in the medical device. The size, the shape, the structure of those oak trees really creates the long-term surface performance that we're looking for," Lucchino said. "Our ability to disrupt the way bacteria and blood components interact with medical devices is a huge deal."
GlaxoSmithKline (NYSE:GSK)'s venture capital arm, SR One, and Foundation Medical Partners co-led the round. Prior backers 5AM Ventures and Pangaea Ventures also joined the round, which brought Semprus' total equity financing to $28.5 million, according to a press release. In connection with the Series B round, Foundation Medical Partners principal John Sullivan and SR One partner Dr. Simeon George will join the Semprus board of directors.
Terumo strikes a deal with Olympus for its GlideWire urology device, 2 years after spiking a similar...
Tandem Diabetes is taking orders for its new t:flex insulin pump, 4 months after FDA officials...
Iceland's Össur develops bionic implants that allow amputees to control prosthetic limbs with their...
Biolase lures Zimmer Dental president Harold Flynn to be its new CEO.